Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 21 Ha'arba'a St. TEL AVIV-YAFO 6473921 |
Tel: | 1-972-36398893 |
Website: | https://www.redhillbio.com |
IR: | See website |
Key People | ||
Dror Ben-Asher Chairman of the Board, Chief Executive Officer | Razi Ingber Chief Financial Officer | Gilead Raday Chief Operating Officer |
Patricia Anderson Senior Vice President - Regulatory Affairs | Reza Fathi Senior Vice President - Research and Development | Rick D. Scruggs Chief Commercial Officer, Director |
June S. Almenoff Chief Medical Officer | Adi Frish Chief Corporate and Business Development Officer | Guy Goldberg Chief Business Officer |
Business Overview |
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers' diarrhea. RedHill's clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting. |
Financial Overview |
For the fiscal year ended 31 December 2023, RedHill Biopharma Ltd (ADR) revenues decreased 89% to $6.5M. Net income totaled $23.9M vs. loss of $71.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Interest and royalties expenses related decrease from $40.9M (expense) to $0K, SELLING, MARKETING AND BUSINESS DEVELOP decrease of 69% to $4.4M (expense). |